ストックスクリーナーアプリを入手
25.13
2.77%
-0.69
前日終値:
$25.82
開ける：
$25.63
24時間の取引高:
528.94K
Relative Volume:
0.26
時価総額：
$2.77B
収益：
$12.59M
当期純損益:
$-212.39M
株価収益率:
-8.1451
EPS:
-3.0853
ネットキャッシュフロー:
$-185.92M
1週間 パフォーマンス:
+12.03%
1か月 パフォーマンス:
+15.53%
6か月 パフォーマンス:
+119.26%
1年 パフォーマンス:
+145.65%
1日の値動き範囲:
$25.07
$26.36
1週間の範囲:
$21.39
$26.36
52週間の値動き範囲:
$5.1501
$26.36
Immunome Inc Stock (IMNM) Company Profile
IMNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
25.09 | 2.85B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-01 | 開始されました | Truist | Buy |
| 2025-09-22 | 開始されました | Goldman | Buy |
| 2025-09-05 | 開始されました | Craig Hallum | Buy |
| 2025-04-02 | 開始されました | Lake Street | Buy |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-04-30 | 開始されました | JP Morgan | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-01-29 | 開始されました | Leerink Partners | Outperform |
| 2023-12-19 | 開始されました | Wedbush | Outperform |
| 2021-10-29 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Immunome Inc (IMNM) 最新ニュース
(IMNM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunome stock reaches 52-week high at $25.32 By Investing.com - Investing.com Nigeria
Immunome (NASDAQ:IMNM) Hits New 12-Month HighWhat's Next? - MarketBeat
Immunome stock reaches 52-week high at $25.32 - Investing.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Nasdaq Moves: What is the long term forecast for Immunome Inc stockJuly 2025 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Sentiment Recap: Is Immunome Inc a good stock for dollar cost averaging2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA PlanWhat's Changed - simplywall.st
Bond Watch: Does Immunome Inc have declining or rising EPSEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat SuccessHas The Bull Case Changed? - Yahoo Finance
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance
Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC - MarketBeat
Is Immunome Inc affected by consumer sentiment2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Tar - GuruFocus
Immunome (NASDAQ:IMNM) Trading 8.1% HigherHere's Why - MarketBeat
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Insider Monkey
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush - MarketBeat
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation - Sahm
Returns Recap: Does Immunome Inc have declining or rising EPSWeekly Trade Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Responsive Playbooks and the IMNM Inflection - Stock Traders Daily
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms - TechStock²
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Insider Monkey
Is Immunome Inc. stock supported by strong fundamentalsMarket Rumors and News & Affordable Market Investment - Улправда
Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" - Finviz
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Franklin Credit Management CorporationImmunome to Present at 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update - TechStock²
Immunome’s Stock Under the Microscope: Can IMNM Turn Recent Volatility Into a Breakout? - AD HOC NEWS
Immunome (NASDAQ:IMNM) Shares Down 7%Time to Sell? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Decliners Report: Can Immunome Inc stock deliver strong Q4 earningsJuly 2025 Outlook & Weekly High Return Opportunities - Bộ Nội Vụ
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer? - MSN
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com South Africa
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Former CEO Of Seagen Buys Shares Of Immunome – Insider Weekends (NASDAQ:IMNM) - Seeking Alpha
Why Immunome stock surged today - MSN
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm
Immunome (IMNM) price target increased by 33.44% to 34.94 - MSN
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat
Guggenheim reiterates Buy rating on Immunome stock following $400M financing By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Immunome stock following $400M financing - Investing.com Nigeria
Immunome Inc (IMNM) 財務データ
収益
当期純利益
現金流量
EPS
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):